Factor VIII (Factor VIII, Ipsen / Hyate C / Hyate)

The Influence of Freezing Methodology on Coagulation Factor Preservation in Fresh Frozen Plasma: A Pilot Study.

Pawar Amit Ajay AA, Tomar Akshaya A, Sharma Anoop A, Sadana Ushasree U et al.

Rapid freezing is thought to better preserve labile coagulation factors in Fresh Frozen Plasma (FFP). This pilot study compared Contact Shock Freezing (CSF) with Conventional Freezing (CF) to assess their effectiveness in maintaining post-thaw coagulation factor levels. Although the ABO blood group may influence plasma characteristics, its role was not a primary objective and was only noted for preliminary observation during the comparison of the two freezing methods. In a prospective pilot study, plasma from 75 donors (balanced by ABO group) was divided into matched aliquots and subjected to either CSF (30 min at -30°C) or CF (7-8 hours at -30°C). Post-thaw analyses of PT, aPTT, fibrinogen, factor V, factor VIII, and factor IX were performed. Non-parametric statistics (Wilcoxon Signed-Rank tests and Aligned Ranks Transform ANOVA) were used for analysis. Study data suggested a trend towards superior preservation with CSF, yielding lower median PT and aPTT and higher median activities of Fibrinogen, Factor V, and Factor VIII. Notably, statistically significant interaction effects between the freezing method and ABO group were observed for fibrinogen (p=0.033), Factor VIII (p=0.012), and Factor IX (p=0.003). Post-hoc analysis indicated that the potential benefit of CSF for Fibrinogen may be most pronounced in group AB, and for Factor VIII in group B, while CF might better preserve Factor IX in group A. This in vitro pilot study demonstrates that Contact Shock Freezing is superior to Conventional Freezing in preserving the coagulation integrity of Fresh Frozen Plasma across all major parameters. The observed ABO-related differences emerged as incidental exploratory findings and should be interpreted with caution. The clinical significance of these biochemical improvements requires further investigation in well-designed clinical outcome studies.

Subcutaneous Treatment Hope: Non-Factor Care in Children with Hemophilia.

Thom Katharina K

Hemophilia A or B is an inherited bleeding disorder due to a deficiency of factor VIII or IX. Depending on the severity, bleeding may already occur after birth and in very young patients, e.g., intracranial hemorrhage or bleeding in muscle, soft tissue, and joints during surgery or after little accidents. Despite great improvements in factor therapy concerning half-life and less frequent injections, remaining issues are the intravenous administration and inhibitor development. Additionally, a primary regular factor prophylaxis maybe more effective to prevent joint bleeds and damages in adolescence and adults. Non-factor therapies have been a so-called "game changer" in hemophilia care, most of all due to the subcutaneous application and improved quality of life. Existing data demonstrate a more stable coagulation activation and effective bleeding prevention, also in patients with inhibitors. These novel therapies work either as factor mimetics, providing similarity to the missing factor, or they have a rebalancing effect by targeting natural coagulation inhibitors, such as tissue factor pathway inhibitor, or protein C. Depending on data and the approval situation, these therapies may allow an easier and earlier start of prophylaxis and potentially prevent early bleeding. However, concerns about these new treatments include, e.g., risk of coagulation imbalances and insufficient monitoring. This review will comprise an overview of non-factor treatment, such as FVIII mimetics and re-balancing therapies, including working profile, pediatric data, and approval situation in Europe, Switzerland, and the United States.

First Report of Bilateral Avascular Necrosis (AVN) of the Femoral Heads in a Patient with Dual Factor V Deficiency and Factor V Leiden Mutation: A Unique Coagulopathy Intersection with Therapeutic Insights.

Li Wei W, Li Huibo H, Dou Xixi X, Zheng Deqiang D et al.

We present what appears to be the first documented case worldwide of bilateral avascular necrosis (AVN) of the femoral heads in a young adult with the rare co-occurrence of congenital factor V (FV) deficiency and heterozygous FV Leiden mutation.

Corrigendum to "Xanthoxylin alleviates dextran sulfate sodium (DSS)-induced colitis by targeting macrophage infiltration via the tumor necrosis factor (TNF)/nuclear factor-kappa B (NF-κB) signaling pathway" [Phytomedicine 153:157971 (2026) PMID: 41720014].

Chen Yuxin Y, Chen Ziyan Z, Li Jiacheng J, Zhao Rui R et al.